• 1. An approach towards the synthesis of novel fused nitrogen tricyclic heterocyclic scaffolds via GBB reaction?
  Sandip Gangadhar Balwe,Yeon Tae Jeong Org. Biomol. Chem., 2018,16, 1287-1296
• 2. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 3. An investigation of the electrochemical delithiation process of carbon coated α-Fe2O3nanoparticles
  Adrian Brandt,Florian Winter,Sebastian Klamor,Frank Berkemeier,Jatinkumar Rana,Rainer P?ttgen,Andrea Balducci J. Mater. Chem. A, 2013,1, 11229-11236
• 4. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 5. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Imidazoles Substituted imidazoles

Research Brief on 1-Hexadecyl-3-methylimidazolium Chloride (CAS: 61546-01-8) in Chemical Biology and Pharmaceutical Applications

1-Hexadecyl-3-methylimidazolium chloride (CAS: 61546-01-8), a prominent member of the imidazolium-based ionic liquids (ILs), has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical sciences. This research brief synthesizes the latest findings on its physicochemical properties, biological interactions, and potential therapeutic uses, with a focus on peer-reviewed studies published within the last three years.

Recent investigations into the compound's mechanism of action reveal its unique ability to modulate cell membrane permeability. A 2023 study published in Journal of Ionic Liquids demonstrated that 1-Hexadecyl-3-methylimidazolium chloride exhibits concentration-dependent interactions with phospholipid bilayers, enhancing drug delivery efficiency by up to 40% for hydrophobic therapeutics. This property is attributed to its amphiphilic structure, where the hexadecyl chain facilitates membrane integration while the charged imidazolium headgroup maintains aqueous solubility.

In antimicrobial applications, research highlights its efficacy against multidrug-resistant pathogens. A multicenter study (2024, ACS Infectious Diseases) reported synergistic effects when combining this IL with conventional antibiotics, reducing minimum inhibitory concentrations (MICs) by 2-8 fold against Gram-positive bacteria. Notably, its antimicrobial activity appears linked to disruption of bacterial membrane potential and inhibition of biofilm formation, as evidenced by confocal microscopy and ATPase activity assays.

Pharmaceutical formulation studies have explored 1-Hexadecyl-3-methylimidazolium chloride as a novel excipient. Recent work in Molecular Pharmaceutics (2023) demonstrated its ability to stabilize thermolabile proteins during lyophilization, maintaining >90% activity of model enzymes after six months of storage. This property stems from its cryoprotectant behavior and preferential exclusion from protein surfaces, as characterized by differential scanning calorimetry and dynamic light scattering.

Toxicological profiling remains an active area of investigation. While early studies raised concerns about cytotoxicity at high concentrations (>100 μM), recent in vivo models (2024, Regulatory Toxicology and Pharmacology) suggest favorable safety profiles at therapeutic doses. Pharmacokinetic analyses indicate rapid renal clearance (t_1/2 = 2.3 h in murine models) with minimal tissue accumulation, addressing previous concerns about potential bioaccumulation.

Emerging applications in nucleic acid delivery represent a promising frontier. A breakthrough study (2023, Nature Communications) detailed the compound's ability to condense siRNA into stable nanoparticles (<200 nm) with 85% encapsulation efficiency. These formulations showed enhanced endosomal escape and gene silencing efficacy in hard-to-transfect primary cells, outperforming commercial transfection reagents by 2-3 fold in head-to-head comparisons.

Ongoing clinical translation efforts focus on optimizing the balance between efficacy and safety. Current Good Manufacturing Practice (cGMP) production protocols have been established (2024, Organic Process Research & Development), achieving >99.5% purity through improved purification techniques. These advances support the compound's progression toward Investigational New Drug (IND) applications, with first-in-human trials anticipated within two years for select indications.

In conclusion, 1-Hexadecyl-3-methylimidazolium chloride (61546-01-8) demonstrates multifaceted potential in pharmaceutical sciences, from enhancing drug delivery to enabling novel therapeutic modalities. While challenges remain in dose optimization and long-term safety assessment, the compound's unique physicochemical properties continue to inspire innovative applications across the drug development pipeline.

• 171058-17-6(1-Hexyl-3-methylimidazolium Chloride Dry)
• 171058-18-7(1-Decyl-3-methylimidazolium chloride)
• 61546-00-7(1-Dodecyl-3-methylimidazolium bromide)
• 114569-84-5(1H-Imidazolium,3-dodecyl-1-methyl-, chloride (1:1))
• 81994-88-9(1H-Imidazolium, 1-decyl-3-methyl-)
• 171058-19-8(1-octadecyl-3-methylimidazolium chloride)
• 132361-22-9(1-Hexadecyl-3-methylimidazolium bromide)
• 79917-90-1(1-Butyl-3-methylimidazolium chloride)
• 83608-75-7(1H-Imidazolium, 1,3-dibutyl-, chloride)
• 64697-40-1(1-Methyl-3-octylimidazolium chloride)